Title
Plasma and liver lipidomics response to an intervention of rimonabant in ApoE*3Leiden.CETP transgenic mice
Author
Hu, C.
Wei, H.
van den Hoek, A.M.
Wang, M.
van der Heijden, R.
Spijksma, G.
Reijmers, T.H.
Bouwman, J.
Wopereis, S.
Havekes, L.M.
Verheij, E.
Hankemeier, T.
Xu, G.
van der Greef, J.
Publication year
2011
Abstract
Background: Lipids are known to play crucial roles in the development of life-style related risk factors such as obesity, dyslipoproteinemia, hypertension and diabetes. The first selective cannabinoid-1 receptor blocker rimonabant, an anorectic anti-obesity drug, was frequently used in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m2 with associated risk factors such as type II diabetes and dyslipidaemia in the past. Less is known about the impact of this drug on the regulation of lipid metabolism in plasma and liver in the early stage of obesity. Methodology/Principal Findings: We designed a four-week parallel controlled intervention on apolipoprotein E3 Leiden cholesteryl ester transfer protein (ApoE&z.ast;3Leiden.CETP) transgenic mice with mild overweight and hypercholesterolemia. A liquid chromatography-linear ion trap-Fourier transform ion cyclotron resonance-mass spectrometric approach was employed to investigate plasma and liver lipid responses to the rimonabant intervention. Rimonabant was found to induce a significant body weight loss (9.4%, p
Subject
EELS - Earth, Environmental and Life Sciences
Life
Health
MHR - Metabolic Health Research MSB - Microbiology and Systems Biology
To reference this document use:
http://resolver.tudelft.nl/uuid:92c9a9d9-f572-4a8d-9bda-7a526699118f
DOI
https://doi.org/10.1371/journal.pone.0019423
TNO identifier
429702
ISSN
1932-6203
Source
PLoS ONE, 6 (6)
Document type
article